An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
SALT LAKE CITY--(BUSINESS WIRE)--
BioHive, Utah’s collective of life sciences and healthcare innovation companies, today announced that Katelin Roberts will serve as the full time Executive Director, effective immediately. Roberts has been serving as interim Executive Director since the launch of BioHive last year. BioHive’s mission is to brand, build and bring together Utah’s robust and growing life sciences industry.
BioHive, with a mission to brand, build and bring together Utah's robust and growing life sciences industry, names Katelin Roberts Executive Director. (Photo: Business Wire)
Roberts brings a broad range of leadership experience in the life sciences from operations and manufacturing to investing. Most recently, she served as Chief Executive Officer of Line Logic, a company with an innovative catheter stabilization device on the market. Roberts is also a partner with MedMountain Ventures where she will stay on in a non-operating investing role.
Chris Gibson, Co-Founder and CEO of Recursion (NASDAQ: RXRX) and Founding Chairman of BioHive said, “What is happening in the BioHive is so exciting and I am tremendously excited that we will now have Katelin’s full attention focused on telling our story, bringing together the life sciences community here in Utah and building up the future of this great hub. Katelin is an excellent leader and I know I speak for the broader community when I say that we are all excited to get to work alongside her.”
“I am thrilled to take on this role and work more closely with our industry, it’s employees and the patients we serve,” Roberts said. “Utah has transformative science and technology, and BioHive will be the leader for accelerating life sciences by highlighting our successes and connecting people, talent and capital. Our secret sauce in Utah is our community, and we have the right partners supporting BioHive. If you work in this industry or you support the industry, you’re already a member of BioHive and the work you are doing is important and valuable.”
BioHive is a chartered organization of BioUtah, Utah’s trade organization for the life sciences. Kelvyn Cullimore, CEO and President of BioUtah added “BioUtah strongly supports the mission of BioHive as they tackle initiatives to brand, build and coalesce our ecosystem. We look forward to collaborating to sponsor events and promotions to strengthen and improve our community. I’ve worked with Katelin over the last year and know of her excellent skill sets and passion for shining a bright light on the successes of the life sciences industry in Utah.”
About BioHive
BioHive is a thriving collective of more than 1,100 companies representing the life sciences and healthcare innovation ecosystem of Utah’s economy. We embrace diversity and promote collaboration. BioHive includes researchers, developers and manufacturers of therapeutics, devices and diagnostics, as well as laboratory facilities, healthcare delivery systems, digital health, health IT and supply-chain businesses that support these industries. We’ve been the fastest-growing life sciences community in America since 2012, employing 43,000 people directly and 88,000 indirectly, for a total of more than 130,000. Empowered by this rich talent pool, BioHive is leading the way with crucial innovations that boost our state’s economy and help patients around the globe.
recursion pharmaceuticals has developed a powerful drug discovery platform involving millions of rapid, automated experiments and analysis to discover new therapeutics. our platform has resulted in the massive parallelization of drug discovery. we have deployed this platform in pursuit of drugs for the treatment of rare genetic diseases. we partner or out-license these leads to major pharmaceutical companies early in development. our horizontal business model focused on discovery accelerates our impact and reduces our costs by avoiding slow and costly in-house development, and allows us to spread risk across many new therapeutic opportunities.
